NCT06663358View on ClinicalTrials.gov

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions
Fabry Disease
Interventions
DRUG

Pegunigalsidase-alfa

Administered via intravenous (IV) infusion under conditions of routine clinical care

Trial Locations (1)

49525

RECRUITING

Infusion Associates, Grand Rapids

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY